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Background: Ventricular tachyarrhythmias (VTs) are life-threatening events that result in hemodynamic
compromise. Recurrence is common and may worsen a patient's clinical course despite appropriate
treatment. This study aimed to examine the effectiveness of antiarrhythmic drugs for suppression of VTs.
Methods: In this cohort study, eligible patients were those who were admitted to one of the nine car-
diovascular care centers and treated with continuous infusion of an antiarrhythmic drug for at least 1 h
to prevent recurrence of VTs after return of spontaneous circulation. To adjust for differences in baseline
characteristics among treatment groups, propensity scores for administered agents were generated and
used as covariates in regression analyses.
Results: Seventy-two patients were enrolled and 67 patients were included in the ﬁnal analysis. Amio-
darone (n¼21, 31.3%), nifekalant (n¼24, 35.8%), and lidocaine (n¼22, 32.8%) were administered as ﬁrst-
line therapy for suppression of VTs. In the adjusted analyses, the odds ratio (OR) of switching to a dif-
ferent drug was signiﬁcantly higher in the lidocaine group (OR 37.6, 95% CI 5.1–279, po0.001) than in
the amiodarone group, but not in the nifekalant group (OR 4.1, 95% CI 0.72–23.2, p¼0.11). There was no
signiﬁcant difference in mortality rate in the lidocaine group (OR 1.67, 95% CI 0.40–6.95, p¼0.48) or the
nifekalant group (OR 1.11, 95% CI 0.15–4.85, p¼0.89) compared with the amiodarone group.
Conclusion: Amiodarone and nifekalant are similarly effective in preventing VT recurrence, but their
impact on survival rate is minimal. These data indicate that both nifekalant and amiodarone can be used
for treatment of refractory VT.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ventricular tachyarrhythmias (VTs) are life-threatening events
that result in hemodynamic compromise; therefore, patients often
require immediate treatment such as electrical cardioversion.
Despite appropriate management of ventricular arrhythmias,
recurrence is common and may worsen the clinical course of the
patients. The American Heart Association (AHA) guideline on
cardiopulmonary resuscitation (CPR) and emergency cardiovas-
cular care states that when ventricular arrhythmias are refractory
to deﬁbrillation, antiarrhythmic agents, such as amiodarone,
lidocaine, and magnesium sulfate, can be used [1,2].
Lidocaine has been used empirically for the prevention of
ventricular arrhythmias. However, when compared to amiodarone,
it has not been demonstrated to improve the return ofblished by Elsevier B.V. This is an
þ81 116650242.
ki),spontaneous circulation (ROSC) or survival to hospital discharge.
Some studies suggested that amiodarone was superior to lidocaine
for the management of ventricular arrhythmias [3,4]. However, its
antiarrhythmic effect has a late onset, and a large dose is needed
to terminate ventricular arrhythmias in emergent settings. Fur-
thermore, bradycardia and hypotension may occur after resusci-
tation as a result of its β-adrenergic blocking effect and vasoactive
effect of the excipients, polysorbate 80 and benzyl alcohol [5].
Nifekalant, a pure potassium channel blocker, was clinically
approved and is currently used only in Japan. Although some
reports suggested that nifekalant was efﬁcient for the treatment of
refractory ventricular arrhythmias, only a small number of studies
have directly compared class III drugs because it is difﬁcult to carry
out a randomized study in an emergent and critical care setting
[6–11].
Once an antiarrhythmic agent is effective for deﬁbrillation or
suppression of malignant arrhythmias, most physicians continue
administering it for a certain period, but the optimal drug and
duration of the therapy for the prevention of arrhythmiaopen access article under the CC BY-NC-ND license
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study to investigate the role of antiarrhythmic agents for sup-
pression of ventricular arrhythmias in clinical practice.2. Material and methods
2.1. Study setting
This observational cohort study was conducted at nine cardi-
ovascular centers in Chiba prefecture in Japan from 2005 to 2009.
2.2. Patient enrollment
Patients who were treated with a continuous infusion of
intravenous antiarrhythmic agents for at least 1 h to prevent the
recurrence of ventricular arrhythmias in a hospital setting were
eligible for enrollment. When a patient was unstable due to sus-
tained ventricular arrhythmias at presentation, electrical cardio-
version was immediately delivered to stabilize hemodynamics,
and then antiarrhythmic therapy was initiated to prevent
arrhythmia recurrence. The choice of a speciﬁc antiarrhythmic
drug depended on each physician, and was in line with the major
guidelines for CPR and ventricular arrhythmias.
After obtaining the patients’ informed consent, these were
enrolled within 48 h after administration of preventive antiar-
rhythmic drugs and their clinical course was followed until dis-
charge. Patients’ baseline data were collected to adjust for their
potential confounding effect on the choice of treatment and out-
comes. The baseline data included age, sex, underlying heart dis-
eases, cardiac function, administered drugs and their dose and
duration, and clinical courses and outcomes. The ethical commit-
tee in each hospital approved this study design.
2.3. Exclusion criteria
Patients were not eligible if they met any of the following cri-
teria: multiple antiarrhythmic drugs were administered intrave-
nously from the beginning, oral antiarrhythmic agents were being
taken at the time of hospital admission, treatment was with a
single-shot antiarrhythmic drug only, or an intravenous antiar-
rhythmic agent was administered for less than 1 h. These situa-
tions were considered to hinder the evaluation of suppressive
effects of the antiarrhythmic drugs.
2.4. Outcomes deﬁnition
In the evaluation of drugs effectiveness, the primary outcome
was deﬁned as any switch or addition of an antiarrhythmic drug
due to their ineffectiveness or adverse effect. The purpose of
prophylactic antiarrhythmic drugs after resuscitation care is to
prevent recurrent ventricular arrhythmias deteriorating the
hemodynamic state, but the criteria of drug effectiveness was not
well established. In the case of recurrent ventricular arrhythmias
immediately after initiation of an antiarrhythmic drug, it is difﬁ-
cult to determine whether the drug is effective due to its short
course duration. Once we determine that the drug is ineffective or
harmful regardless of the reason, we usually switch it to another
drug or add other drugs to it; therefore, we considered this deﬁ-
nition as an appropriate indicator in this study.
The secondary outcome was survival at discharge. The drug
adverse effects were also investigated for drug safety. The dis-
tinction between interruption and completion of drug adminis-
tration depended on whether the drug was switched to another
intravenous drug. The end of intravenous administration wasconsidered when drug cessation occurred without switching to an
oral drug or with switching to the same drug in oral form.
2.5. Statistical analysis
Values were expressed as the mean7standard deviation when
the data were normally distributed data or the media-
n7 interquartile range when the data did not follow a normal
distribution. Continuous baseline variables were compared among
groups by one-way analyses of variance. Categorical baseline
variables were compared by Chi-square test or Fisher's exact test,
as appropriate. Because of a relative small number of patients in
logistic regression analysis that included multiple covariates,
propensity scores were generated to estimate the probability of
treatment assignment by using multinomial logistic regression,
and the propensity scores were used as a single covariate in the
logistic regression analysis. The variables for estimating propensity
scores included age, sex, prehospital cardiopulmonary arrest,
electrical cardioversion, ischemic or nonischemic heart disease,
types of ventricular arrhythmias (monomorphic, polymorphic
ventricular tachycardia or ventricular ﬁbrillation), use of beta-
blockers, and inotropes or mechanical hemodynamic support
before antiarrhythmic drug administration. In order to determine
the validity of the comparisons adjusted by propensity scores, the
distribution and overlap of the calculated propensity scores were
checked for each agent. A variance inﬂation factor was employed
to investigate independent variables multicollinearity. In the
analysis comparing the difference between two antiarrhythmic
agents, the inverse propensity score weighting method was
employed. A two-tailed p value o0.05 was considered signiﬁcant.
All statistical analyses were performed by R version 3.2.0.3. Results
3.1. Primary and secondary outcomes
A total of 72 patients were enrolled in this study. Five of them
were excluded based on exclusion criteria, and the other 67 were
analyzed using the regression model as they had presented with
complete data (Fig. 1). Their baseline characteristics and clinical
outcomes are shown in Tables 1 and 2, respectively. Amiodarone
was administered as the ﬁrst-line therapy in 21 patients, lidocaine
in 22 patients, and nifekalant in 24 patients. There were signiﬁcant
differences in baseline characteristics among these groups, such as
in the prevalence of cardiopulmonary arrest on arrival and use of
inotropic agents.
In crude analysis, lidocaine use was signiﬁcantly associated
with a subsequent drug change or addition when compared with
amiodarone use (odds ratio (OR) 12.9, 95% conﬁdence interval (CI)
2.82–58.6, p¼0.001) (Table 3). There was no difference among the
three agents in survival at discharge (p¼0.694).
Furthermore, in the adjusted analyses using propensity scores,
a drug change to another agent occurred signiﬁcantly more often
in the lidocaine group (OR 34.2, 95% CI 4.62–253, po0.001) when
compared with the amiodarone group, but not in the nifekalant
group (OR: 4.63, 95% CI: 0.81–26.5, p¼0.086). However, there
were no signiﬁcant differences in survival at discharge when the
amiodarone group was compared with the lidocaine and nifeka-
lant groups, respectively (lidocaine group: OR 1.67, 95% CI 0.40–
6.95, p¼0.48; nifekalant group: OR 1.11, 95% CI 0.15–4.85, p¼0.89).
In post-hoc analysis, amiodarone and nifekalant groups were
compared by using the inverse propensity score weighting
method. This analysis showed no signiﬁcant difference in the rate
of drug change or addition (OR 0.245, 95% CI 0.045–1.318,
Fig. 1. Flow chart of enrolled patients and their outcomes.
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0.236–5.20, p¼0.898) (Table 4).
3.2. Adverse effects
When conducting adverse events surveys, three patients had
hypotension, bradycardia, and signiﬁcant liver dysfunction (liver
enzyme values43 times normal values). Additionally, interstitial
pneumonia occurred in one of the patients in the amiodarone
group. Moreover, of the 23 patients treated with nifekalant, three
experienced prolonged QT interval or torsades de pointes. In the
lidocaine group, three patients complained of nausea or vomiting,
presumably due to drug intoxication. In all of these cases, the
drugs were discontinued. Data on the plasma concentration of
each drug were not available.4. Discussion
In management of ventricular arrhythmias, amiodarone plays a
pivotal role in clinical practice, and current guidelines have
recommended it as the ﬁrst choice for intravenous infusion in
cases of ventricular arrhythmias refractory to deﬁbrillation. For a
decade, nifekalant has been the only approved class III agent in
Japan. It was demonstrated to suppress ventricular re-entry by
prolonging the action's potential duration and effective refractory
period without evidencing a negative inotropic effect [12–16].
Furthermore, this agent causes dose-dependent QT prolongation
and torsade de pointes. In other countries, intravenous amiodar-
one has already been used for a few decades and has been
established as a mainstay drug for various types of arrhythmias.
After the clinical introduction of intravenous amiodarone in Japan,
we could not determine which agent was superior for fetal ven-
tricular arrhythmias treatment because there were a small number
of clinical studies directly comparing these agents. One study
reported that nifekalant was not inferior to amiodarone for the
treatment of out-of-hospital cardiac arrest due to shock-resistant
ventricular ﬁbrillation [17]. Since most VTs are life threatening,
one cannot afford to spare time to obtain appropriate informed
consent or to randomly choose antiarrhythmic drugs. A cluster
randomization method may be a practical and promising solution
to meet this need.According to our registry, three antiarrhythmic agents were
used. These are amiodarone, lidocaine, and nifekalant. Lidocaine
was conventionally used as ﬁrst-line therapy, but several obser-
vational studies and a meta-analysis showed that lidocaine
administration resulted in poor prognosis or no beneﬁt in patients
with acute myocardial infarction, therefore its routine use is not
generally recommended by the current guidelines [18–20]. In
contrast, another study demonstrated that prophylactic adminis-
tration of lidocaine was associated with a decreased number of
recurrent ventricular arrhythmias in post resuscitation periods
[21]. There is insufﬁcient data evaluating the prophylactic uses of
other antiarrhythmic drugs, and 2015 AHA guidelines stated that
there was insufﬁcient evidence on the routine administration of
antiarrhythmic drugs after resuscitation; however, lidocaine might
be considered [1,2].
When compared with lidocaine, both amiodarone and nifeka-
lant were proved similarly effective for ventricular arrhythmias
suppression. These drugs, however, have characteristic adverse
effects, such as negative inotropic and chronotropic outcomes
(amiodarone), and QT prolongation resulting in torsade de pointes
(nifekalant). One should be aware of frequent QT-interval pro-
longation after nifekalant administration. Nevertheless, the QT
interval measurement is often difﬁcult because of abnormal ST- or
T-wave morphology due to ischemia or electrolyte disturbances
after cardiopulmonary resuscitation. However, this agent has
several advantages over amiodarone, such as an early onset and
offset of an antiarrhythmic effect, and a minimal effect on hemo-
dynamics and cardiac contractility. Sotalol has a similar effect but
causes beta-adrenergic blockade, which is contraindicated in
bradycardic patients. Although several studies on nifekalant have
been reported thus far, in most of them, including our study, a
comparison among antiarrhythmic drugs was difﬁcult because of
an insufﬁcient numbers of patients and heterogeneous study
designs [22].
Most of the previous studies consistently showed that anti-
arrhythmic administration had little or no beneﬁt on the in-
hospital mortality, and AHA guideline stated that no drug has
yet been shown to increase the survival or neurological outcome
after a cardiac arrest that is due to ventricular arrhythmias [2].
As with the previous studies, no signiﬁcant differences in mor-
tality were observed among the three antiarrhythmic drugs
used in our study. These ﬁndings suggest that the choice of
Table 1
Baseline demographic and clinical characteristics of the study population by
administered antiarrhythmic agent (N¼67).
Amiodarone Lidocaine Nifekalant p Value
Number 21 22 24
Age 67.3 (13.5) 65.7 (11.0) 68.5 (12.9) 0.754
Sex (female) (%) 6 (28.6) 7 (31.8) 3 (12.5) 0.256
Body weight (kg) 51.3 (10.7) 62.2 (13.7) 61.2 (12.3) 0.082
NYHA 2.0 [1.0, 4.0] 3.0 [1.0, 4.0] 2.0 [1.3, 4.0] 0.943
Left ventricular ejection
fraction (%)
40.0 (12.4) 39.3 (10.6) 36.8 (15.9) 0.735
Underlying heart disease
(%)
ACS 11 (52.4) 7 (31.8) 8 (33.3) 0.458
IHD other than ACS 4 (19.0) 10 (45.5) 6 (25.0)
Valvular disease 0 (0.0) 1 (4.5) 1 (4.2)
Cardiomyopathy 4 (19.0) 2 (9.1) 6 (25.0)
Idiopathic/LQT/Brugada
syndrome
1 (4.8) 2 (9.1) 3 (12.5)
Myocarditis 1 (4.8) 0 (0.0) 0 (0.0)
Cardiopulmonary arrest
(%)
1 (4.8) 10 (45.5) 4 (16.7) 0.004
IABP/ECMO use (%) 9 (42.9) 5 (27.8) 7 (30.4) 0.555
Revascularization (%) 11 (52.4) 11 (50.0) 8 (33.3) 0.367
B-type natriuretic pep-
tide (pg/ml)
128 (143) 384 (281) 775 (489) 0.125
Systolic blood pressure
(mmHg)
112 (16.9) 95 (8.5) 105 (25.2) 0.269
Serum creatinine (mg/dl) 1.66 (0.98) 1.23 (0.38) 1.93 (2.05) 0.438
Corrected QT interval
(ms)
483 (55.1) 504 (58.6) 476 (46.3) 0.561
Heart rate before admin-
istration (beats per
min)
77.7 (9.6) 77.6 (18.9) 94.3 (17.7) 0.076
Use of an inotropic agent
(%)
12 (57.1) 6 (27.3) 14 (60.9) 0.050
Beta blocker use (%) 5(23.8) 4(18.2) 10(41.7) 0.180
Prior cardiac surgery (%) 2 (9.5) 1 (4.5) 2 (8.3) 0.808
Single-shot use of antiar-
rhythmic (%)
Amiodarone 4 (19.0) 0 (0.0) 0 (0.0) o0.001
Lidocaine 3 (14.3) 8 (36.4) 8 (33.3)
Nifekalant 4 (19.0) 0 (0.0) 12 (50.0)
Oral antiarrhythmic (%) 1(4.8) 1 (4.5) 3 (12.5) 0.503
Electrical cardioversion
(%)
19 (90.5) 17 (77.3) 15 (62.5) 0.089
Type of ventricular
arrhythmia (%)
Monomorphic VT 8 (38.1) 12 (54.5) 16 (66.7) 0.050
Polymorphic VT/VF 9 (42.9) 10 (45.5) 8 (33.3)
Unknown 4 (19.0) 0 (0.0) 0 (0.0)
Data are expressed as mean (standard deviation, SD), median [interquartile, IQR]
and number (%).
NYHA, New York Heart Association functional classiﬁcation; ACS, acute coronary
syndrome; IHD, ischemic heart disease; LQT, long QT syndrome; IABP, intra-aortic
balloon pump; ECMO, extracorporeal membrane oxygenation; VT, ventricular
tachycardia; VF, ventricular ﬁbrillation.
Table 2
Clinical outcomes by administered antiarrhythmic agents.
Amiodarone Lidocaine Nifekalant P value
Number 21 22 24
Drug switching (%) 3 (14.3) 15 (68.2) 6 (25.0) o0.001
Deﬁbrillation after 1-h
administration (%)
2 (9.5) 3 (13.6) 6 (25.0) 0.421
Survival at discharge (%) 15 (71.4) 14 (63.6) 18 (75.0) 0.694
Ablation targeted for VT (%) 1 (4.8) 2 (9.1) 3 (12.5) 0.634
Taking oral antiarrhythmic
agents at discharge (%)
10 (47.6) 10 (45.5) 11 (47.8) 0.985
Duration of intravenous
administration (hour)
56.1 (40.7) 105.4
(123.4)
83.6
(115.5)
0.503
Cumulative dose (g) 1.52 (1.05) 8.38
(11.7)
1.23 (1.77) a
Deﬁbrillator implantation (%) 6 (28.6) 3 (13.6) 8 (34.8) 0.252
Data are expressed as mean (standard deviation, SD) or number (percentage).
a The standard dosage varies among agents and no statistical analysis was
conducted.
Table 3
Outcomes by individual antiarrhythmic agents in adjusted analyses.
Crude OR
(95% CI)
P value Adjusted OR
(95% CI)
P value
Primary outcome
(Drug switching)
Amiodarone Reference
Lidocaine 12.9 (2.82–
58.6)
o0.001 37.6 (5.1–279) o0.001
Nifekalant 2.0 (0.43–
9.26)
0.38 4.1 (0.72–23.2) 0.11
Secondary outcome
(Survival at discharge)
Amiodarone Reference
Lidocaine 1.43 (0.40–
5.16)
0.59 1.67 (0.40–
6.95)
0.48
Nifekalant 0.83 (0.22–
3.13)
0.79 1.11 (0.15–
4.85)
0.89
Models were adjusted for age, sex, deﬁbrillation therapy, cardiopulmonary arrest,
use of inotropic agents, and ischemic or nonischemic heart disease. C-statistics for
amiodarone, lidocaine, and nifekalant were 0.764, 0.810, and 0.777, respectively.
OR, odds ratio; CI, conﬁdence interval.
Table 4
Comparison between amiodarone and nifekalant therapies adjusted by inverse
propensity score weighting method.
Crude OR
(95% CI)
p Value Adjusted OR
(95% CI)
p Value
Primary outcome (Drug
switching)
Amiodarone 0.472 (0.102–
2.19)
0.338 0.245 (0.045–
1.318)
0.109
Nifekalant Reference
Secondary outcome (Sur-
vival at discharge)
Amiodarone 1.440(0.366–
5.67)
0.602 1.107(0.236–
5.20)
0.898
Nifekalant Reference
OR, odds ratio; CI, conﬁdence interval.
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ventricular arrhythmias patients. However, we consider that
these drugs exhibit short-term effects when used for the sta-
bilization of patients` status in clinical practice. It is hoped that
long-term beneﬁt will be evaluated in a well-designed
clinical trial.
There are still several questions to be answered: if the ﬁrst drug
fails to prevent ventricular arrhythmia, which antiarrhythmic drug
should be used next; in which patients should antiarrhythmic
agents be used as initial therapy; and can antiarrhythmic drugs
improve outcomes. To answer these important questions, it is
desirable that additional studies be performed with these agents
in emergent or intensive care settings.This study has several limitations. First, it was a non-
randomized study with a small sample size; thus, there is the
possibility of several biases in patient selection. In the lidocaine
M. Suzuki et al. / Journal of Arrhythmia 32 (2016) 186–190190group, the prevalence of cardiopulmonary arrest was relatively
high. However, we adjusted for this effect on outcome in our
univariate logistic regression model, and the results were similar
to those adjusted by propensity scores. Another issue was an over-
ﬁtting in estimating the propensity score in our logistic regression
model. This was due to a small number of events. In this direction,
some previous reports addressed this issue by using propensity
scores as a method of data reduction. Therefore, we handled this
problem in the same fashion [23,24]. In addition, there is no
established method to estimate propensity scores and to compare
effects between more than two treatment arms. We used multi-
nomial logistic regression analysis to generate these scores and
used them in logistic regression as covariates with treatment
categories [25]. The tests of goodness of ﬁt in this model showed
that this hypothesis was acceptable in this study; however, resi-
dual differences may be explained by confounding effects of
variables, such as physician's preference that could not be
measured.5. Conclusions
In our observational study, continuous infusions of both
amiodarone and nifekalant were similarly superior to lidocaine for
suppression of recurrent ventricular arrhythmias.Disclosures
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